The Narooma ventilator dispute is back in focus, shining a light on how emergency public procurement can unravel long after a crisis ends. What began as a pandemic-era agreement for hundreds of ventilators has evolved into a costly legal and financial battle involving arbitration, partial payments, and a separate High Court claim.
At the centre of the case is Dublin-based medical devices company Narooma Limited, which says it is still pursuing part of the money awarded after a collapsed ventilator deal with the HSE. Beyond the legal headlines, the dispute raises broader questions for the technology and medtech sectors about supply chain risk, contract enforcement, and accountability in fast-moving health emergencies.
The Narooma ventilator dispute explained
The Narooma ventilator dispute stems from a Covid-19-era agreement under which the HSE had agreed to buy 350 ventilators in a deal reportedly worth €7.5 million. According to the latest filed company accounts, Narooma Limited is still taking steps to recover amounts awarded following arbitration over the failed contract.
An arbitration ruling by the International Chamber of Commerce’s court ordered the HSE to pay Narooma close to €2.77 million for breach of contract related to the ventilator procurement. The accounts also state that the sum was to carry simple interest at 2 per cent per year from March 19th, 2021, until payment, along with liability for arbitration, legal, and procedural costs.
While the HSE has said it has discharged any applicable payments, including interest, Narooma’s accounts indicate the recovery process was still ongoing as of mid-October this year. Because both sides have pointed to confidentiality obligations, many details remain outside the public domain.
Why this case matters for health technology procurement
The Narooma ventilator dispute is not just a legacy Covid story. It is a revealing case study for technology procurement in healthcare, especially where speed, public need, and complex supply arrangements collide.
During the pandemic, governments and health agencies worldwide raced to secure critical equipment, from ventilators to testing devices and protective gear. In that environment, deals were often struck quickly, sometimes before normal procurement safeguards, due diligence checks, or delivery contingencies could be fully tested.
This case highlights several recurring challenges:
- Contract clarity: Emergency purchasing still requires precise obligations on payment, delivery, acceptance, and cancellation.
- Supplier risk: Medtech firms can face severe financial exposure when public buyers delay or dispute payments.
- Dispute resolution: Arbitration can provide a route to an enforceable outcome, but collection and compliance may still take time.
- Public sector transparency: Confidential proceedings can limit public understanding of how taxpayer-funded procurement failures are resolved.
Financial impact on Narooma Limited
The Narooma ventilator dispute appears to have had a material effect on the company’s finances. Newly filed accounts show Narooma recorded a profit of €1.8 million for its latest financial year, ending in early March, and moved into accumulated profits of nearly €1.7 million.
The company also reported €1.8 million in cash at bank and total assets less current liabilities of close to €1.7 million at year-end. Reporting suggests part of the annual profit was linked to the HSE paying some of the money owed under the arbitration outcome.
That matters because smaller medical technology firms often have limited balance sheet flexibility. When a large public contract collapses, delayed payment can affect:
- Working capital and cash flow
- Inventory financing
- Legal expenditure
- Future product development
- Confidence among partners and investors
For startups and specialist suppliers, contract disputes are rarely just legal matters; they can directly influence survival and growth.
A separate legal front involving IDA Ireland
The Narooma ventilator dispute is also connected to a separate High Court action against IDA Ireland. Narooma has said it intends to continue that claim, which concerns alleged tortious interference with its commercial interests in relation to the same underlying matter.
Court records indicate the case has been listed for mention and adjourned for a further date. IDA Ireland has declined to comment because the matter remains before the courts.
For observers in the technology sector, this second case broadens the story. It suggests the fallout from pandemic procurement may involve not only buyer-supplier disagreements, but also wider institutional relationships around industrial policy, investment support, and strategic manufacturing.
Lessons for medtech and public-sector buyers
For health agencies
- Build crisis procurement frameworks before emergencies happen
- Use clear payment milestones and acceptance criteria
- Document decisions thoroughly for later review
- Balance urgency with legal and operational due diligence
For medical technology companies
- Stress-test contracts for non-payment and cancellation scenarios
- Secure robust legal review on public procurement deals
- Plan for dispute timelines that may last years
- Protect cash flow through diversified customer exposure
The Narooma ventilator dispute underlines a simple truth: even when demand is urgent and public need is obvious, weak contract execution can trigger years of financial and legal consequences.
As healthcare systems continue investing in critical equipment, digital health tools, and resilient supply chains, the lessons from this case should not be ignored. The Narooma ventilator dispute is a reminder that in health technology procurement, speed matters, but enforceable agreements and payment certainty matter just as much.
